- Home
- EXAS vs EXEL Comparison
EXAS vs EXEL Comparison
Compare EXAS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- EXEL
- Stock Information
- Founded
- EXAS 1995
- EXEL 1994
- Country
- EXAS United States
- EXEL United States
- Employees
- EXAS N/A
- EXEL N/A
- Industry
- EXAS Medical Specialities
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EXAS Health Care
- EXEL Health Care
- Exchange
- EXAS Nasdaq
- EXEL Nasdaq
- Market Cap
- EXAS 11.6B
- EXEL 10.0B
- IPO Year
- EXAS N/A
- EXEL 2000
- Fundamental
- Price
- EXAS $59.25
- EXEL $34.37
- Analyst Decision
- EXAS Strong Buy
- EXEL Buy
- Analyst Count
- EXAS 16
- EXEL 17
- Target Price
- EXAS $72.80
- EXEL $32.18
- AVG Volume (30 Days)
- EXAS 2.2M
- EXEL 1.7M
- Earning Date
- EXAS 11-05-2024
- EXEL 02-04-2025
- Dividend Yield
- EXAS N/A
- EXEL N/A
- EPS Growth
- EXAS N/A
- EXEL 441.02
- EPS
- EXAS N/A
- EXEL 1.55
- Revenue
- EXAS $2,692,328,000.00
- EXEL $2,081,598,000.00
- Revenue This Year
- EXAS $11.81
- EXEL $20.59
- Revenue Next Year
- EXAS $11.41
- EXEL $1.50
- P/E Ratio
- EXAS N/A
- EXEL $22.41
- Revenue Growth
- EXAS 11.91
- EXEL 17.31
- 52 Week Low
- EXAS $40.62
- EXEL $19.20
- 52 Week High
- EXAS $79.62
- EXEL $36.97
- Technical
- Relative Strength Index (RSI)
- EXAS 48.86
- EXEL 51.61
- Support Level
- EXAS $61.28
- EXEL $34.30
- Resistance Level
- EXAS $62.15
- EXEL $36.22
- Average True Range (ATR)
- EXAS 2.02
- EXEL 0.75
- MACD
- EXAS 0.15
- EXEL -0.29
- Stochastic Oscillator
- EXAS 3.39
- EXEL 25.09
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.